Medifast, Inc. Announces Acceptance for Publication of Clinical Effi... ( Study of Medifast's effectiveness fo...)

Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study

Date:10/15/2007

Study of Medifast's effectiveness for weight control in patients with type

2 diabetes has been accepted for publication

OWINGS MILLS, Md., Oct. 15 /PRNewswire-FirstCall/ -- Medifast, Inc. (NYSE: MED) today announced that a study conducted by researchers at the Johns Hopkins University Bloomberg School of Public Health has been accepted for publication in a peer-reviewed journal which is scheduled for release in an early 2008 issue. The study compared Medifast's effectiveness for weight control to the standard American Diabetes Association (ADA) recommended dietary guidelines.

"Weight loss is critical for controlling type 2 diabetes," said Michael S. McDevitt, Chief Executive Officer, Medifast, Inc. "Medifast is proud that our products are effective for people who suffer from this disease, and we will continue to work toward improving the health of people with type 2 diabetes."

For more than 25 years Medifast has been prescribed by practitioners as a safe and effective program that yields significant results either alone, or as a complementary low-calorie program with drug therapy. The Medifast brand will be further validated in the medical community, and by consumers, by a second new study recently submitted for publication. The second study which was conducted by researchers at a major university medical institution, shows favorable findings for the Medifast Program among individuals on appetite suppressant therapy.

The Medifast Program alone is proven to provide significant weight loss of 2-5 pounds per week. While the Company does not recommend the use of weight loss drugs, Medifast does recognize that diet pills are very much part of the landscape now and in the future. Medif
'/>"/>

0

GOOD

Page: 1 2
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

Medifast, Inc. Announces Acceptance for Publication of Clinical Effi...( Study of Medifast's effectiveness fo...),Health